Mds 2024 Parkinson Disease

Mds 2024 Parkinson Disease. Abbvie announces positive phase 3 results for parkinson’s drug. All accepted abstracts will be published in an online supplement to movement disorders, the official journal of the international parkinson.


Mds 2024 Parkinson Disease

The oral, specific dopamine agonist met its primary endpoint in the trial, which is the second of. Company to discuss positive results presented at the international mds congress and the design of phase 1b trial in parkinson&closecurlyquote;s disease.

Mds 2024 Parkinson Disease Images References :